Table 3 Second-line therapies

From: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

 

FOLFIRI

FOLFOXIRI

 

Second-line treatment

No patients

%

No patients

%

P -value

Any

102

70

80

58

0.041

L-OHP based

92

63

39

28

0.029

CPT-11 based

10

6

14

10

NSa

Fluoropyrimidines

44

30

29

21

NS

Cetuximab

10

7

7

5

NS

  1. aNS, nonsignificant.
Back to article page